Messages about Treatments

In this closing message to the 75th-Anniversary series, Acting NIMH Director Shelli Avenevoli reflects on a year of celebration and the future of mental health research.

Small businesses are often at the forefront of innovative science, developing new technologies that push mental health research into the future. Learn how NIMH supports small business research through its Small Business Innovation Research Program and Small Business Technology Transfer Program.

The NIMH Intramural Research program has been a world leader in developing and implementing advanced brain imaging technology that has allowed us to delve into the complex circuitry of the human brain. Learn more about their role in developing, implementing, and supporting the use of imaging technology in this guest-written Director’s Message.

In this guest-written Director’s message, the Division of Services and Intervention Research (DSIR) describes notable successes in bridging the gap between basic and clinical science and impacting real-world public health practices and policies.

Did you know that NIMH’s 75 years of mental health research includes over 40 years of HIV research? Learn about NIMH's investments in HIV research in this guest-written Director's message from NIMH's Division of AIDS Research.

Translational research bridges the gap between basic science and impactful mental health solutions. In this guest-written Director’s Message, the NIMH Division of Translational Research discusses past successes, current projects, and future directions of this critical area of work.

This Juneteenth, Dr. Gordon reflects on the persistent mental health disparities experienced by Black Americans and what NIMH is doing to try to reach the goal of true mental health equity.

In this Director’s message, Dr. Gordon introduces the Individually Measured Phenotypes to Advance Computational Translation in Mental Health (IMPACT-MH) initiative. This new groundbreaking NIMH initiative aims to change the game for precision medicine in psychiatry.

In honor of American Heart Month (and Valentine’s Day), Dr. Gordon discusses NIMH’s research activity at the intersection of the heart and the brain.

In this Director’s Message, Dr. Gordon highlights research supported by the NIMH Small Business Innovation Research program that could advance the development of clinically relevant biomarkers.

In this Director’s Message, Dr. Gordon highlights the increased health risks associated with COVID-19 for people with serious mental illness.

In this jointly written Director’s Message, NIMH director Dr. Joshua Gordon and Dr. Maureen Goodenow, associate director for AIDS Research and director of the Office of AIDS Research at the National Institutes of Health, discuss 40 years of NIMH and NIH support for HIV/AIDS research.

In this message for Autism Awareness Month, Dr. Gordon highlights the specific impacts that the COVID-19 pandemic has had for individuals on the autism spectrum and their families.

In this jointly written Director’s Message, leadership from across NIH describes one year of progress made through the RADx initiative and anticipates new challenges in the fight against COVID-19.

In this message for National Eating Disorder Awareness Week, Dr. Gordon highlights NIMH-funded research aimed at reducing the impact of eating disorders.

In Dr. Gordon’s latest Director’s Message, he expresses support for the critical work of NIMH’s Dr. Elisabeth Murray and others who are advancing brain science through basic research.

This week, the National Institute of Mental Health unveiled its new NIMH Strategic Plan for Research. In this Director’s message, Dr. Gordon discusses the advances in knowledge and treatment that got us to where we are today and points to where we want our research to go in the future.

Mental health disparities are significant and easily documented. In this Director’s Message, Dr. Gordon discusses NIMH-funded research that aims to close the gap, ensuring that improved mental health care meets the needs of all Americans.

September is National Suicide Prevention Awareness Month. In observance, Dr. Gordon has partnered with Dr. Volkow, Director of the National Institute on Drug Abuse (NIDA), to highlight a dimension of the opioid crisis that receives too little attention—the links between opioid use, opioid use disorder, and suicide.

In his latest message, Dr. Gordon discusses the role of NIMH and other researchers in the development of esketamine, an FDA-approved, rapid-acting medication that targets treatment-resistant depression.

In this Director’s Message, Dr. Gordon discusses research-based advances in the understanding and treatment of depression.

In this message, Dr. Gordon discusses the role of NIMH and others in the bench-to-bedside story of brexanolone, which has just been approved by the FDA as the first treatment specifically for postpartum depression.

Dr. Gordon discusses NIMH’s role in the HEAL (Helping End Addiction Long-term SM) Initiative -- the National Institutes of Health(NIH)’s all-in, coordinated response to the opioid epidemic.

The American College of Neuropsychopharmacology (ACNP) focuses on research which translates basic neuroscience findings into novel treatments. In this Director’s Message, Dr. Gordon discusses some of the exciting work presented at this year’s ACNP meeting.

After an emergency room visit on Thanksgiving, Dr. Gordon reflects on treatments for injury vs. psychiatric conditions.

Dr. Gordon talks about NIMH’s commitment to support the development and testing of psychosocial interventions in the greater context of the experimental therapeutics approach to treatment research.